Abstract
Nanotechnology has emerged as a transformative tool in the landscape of cancer immunotherapy, offering novel strategies to enhance immune responses and target tumors more precisely. By employing engineered nanoparticles for antigen delivery, immune checkpoint inhibition, and microenvironment modulation, researchers are overcoming limitations associated with conventional immunotherapeutic approaches. This article explores the role of nanomaterials in augmenting both innate and adaptive immune functions while minimizing systemic toxicity. Advancements in nanoscale engineering have enabled the development of targeted delivery platforms and immune-modulatory nanocarriers, setting the stage for more effective and personalized cancer treatment paradigms.
This work is licensed under a Creative Commons Attribution 4.0 International License.